Leadership change Recent leadership transition with a new CEO Emily Schmitz and prior long-time CEO Patricia Meisner indicates a possible appetite for strategic pivots and renewed growth initiatives, presenting an opening to introduce scalable medication reconciliation solutions aligned with leadership priorities.

Growth potential Annual revenue band of 10M to 25M and 51-200 employees position ActualMeds as a growing mid-market partner, suggesting a favorable fit for phased deployments across mid-to-large health systems seeking efficiency in medication reconciliation and care transitions.

Strategic partnerships Recent collaborations with Particle Health and participation in interoperability events (HIMSS25, PointClickCare Summit) highlight a focus on data integration and AI-driven workflows, signaling opportunities to expand with health systems that require robust EHR/HIE data consolidation and AI risk insights.

AI driven value Product emphasizes AI-enabled medication reconciliation and clinically validated risk rules to reduce hospitalizations and readmissions, presenting a strong value proposition for health networks aiming to lower total cost of care and improve transitions of care.

Market fit Positioned as a leader in patient-centered medication management with notable notoriety through clinical trial origins and expansion into enterprise events, enabling outreach to hospitals, health networks, and accountable care organizations seeking BPMH accuracy and workflow automation.